[Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys].
Pancragen may normalize certain hormonal levels in aged monkeys, but its clinical relevance compared to established treatments like glimepiride is unclear.
Where it sits
this study against the rest of the pancragen (kedw) corpusSummary and findings
This study measured the effects of the tetrapeptide Pancragen on hormonal function of the pancreas in old female rhesus monkeys. Nine monkeys were involved, with five receiving Pancragen at a dose of 0.05 mg/animal per day for 10 days, while four received glimepiride at 4 mg/animal per day for the same duration. Both treatments resulted in decreased blood glucose levels, with Pancragen normalizing insulin and C peptide levels.
Abstract
The aim of the investigation was comparative study of the influence tetrapeptide Pancragen (St. Petersburg Institute of Bioregulation and Gerontology, St. Petersburg) on hormonal function of the pancreas compared to the effect of widely used hypoglycemic drug - glimepiride. The investigation involved 9 old (20-25 years) clinically healthy rhesus monkey females (Macaca mulatta). Five of them were injected with Pancragen (0,05 mg/animal per day during 10 days, intramuscularly) for 10 days; 4 animals received glimepiride (4 mg/animal per day during 10 days, per os). Blood samples were taken from all the animals with subsequent analysis of glucose, insulin and C peptide levels; the manipulation was performed before administration of the drugs, on the background of their administration and after their withdrawal in basal conditions, as well as during glucose tolerance testing. Pancragen and glimepiride administration induced the decrease of blood glucose basal levels in both groups of old monkeys. Pancragen also normalized insulin and C peptide levels suggesting its recovering effect on the disturbed tolerance to glucose in old animals. At the same time, glimepiride administration led to a more expressed and delayed hypoglycemic effect and C peptide secretion stimulation without any significant effect on insulin secretion. The data suggest that Pancragen is effective and safe for correction of age-related imbalance of endocrine pancreatic function, and can be used for elderly patient with disturbed glucose tolerance.
Background
The paper addresses the issue of impaired glucose tolerance, a precursor to metabolic disorders, particularly in aging populations. Previous research has indicated that peptides may play a role in glucose metabolism, but the specific effects of Pancragen in this context were not well established. This study aims to fill that gap by investigating the peptide's impact on glucose tolerance in a primate model.
Methods
The study involved old female rhesus monkeys, but specific details regarding the number of subjects (n), dosing regimen, duration of treatment, and the primary versus secondary outcome measures were not reported in the abstract.
Results
Not reported in abstract.
Interpretation
Due to the lack of detailed results, it is challenging to compare the findings with existing literature or to assess the clinical significance of any observed effects. The absence of specific numeric data limits the ability to draw definitive conclusions regarding the peptide's efficacy or safety.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.